Innovations in personalized medicine and cancer diagnostics
CLINICAL24
Diagnostic innovations are driving personalized medicine and cancer diagnostics by moving from a one-size fits all approach, towards highly tailored care. Advances in liquid biopsies, genomic sequencing and biomarker-based tests for example, allows cancer to be characterized at a molecular level, identifying specific mutations, protein expressions, or resistance patterns unique to an individual patient tumor. Diagnostics are now shifting cancer care from reactive to proactive, improving outcomes while reducing unnecessary treatments and side effects.
Bringing automated next-generation sequencing to every oncology clinic
Hear from Kathy Davy, President of Clinical Next Generation Sequencing at Thermo Fisher Scientific, as she shared how the precision oncology is transforming with a fully automated next-generation sequencing (NGS) workflow, allowing even small and community hospitals to deliver rapid, high-quality genomic insights in-house.
Watch interview
Shifting towards scalable cancer diagnostics with AI enabled companion diagnostics
As personalized medicine reshapes oncology, companion diagnostics have become essential to matching patients with targeted therapies. Karan Arora, Leica Biosystems' Senior Vice President of Advanced Assays, discusses current challenges, and his future vision for precision diagnostics.
Read interview
Pioneering regenerative medicine and flow cytometry with Dr. Kalodimou
Dr. Vasiliki E. Kalodimou is an authority in the field and conducts extensive research in stem cells and their applications in regenerative medicine, making significant contributions to the advancement of healthcare. Read this exclusive article to learn more about Dr. Kilodimou's vital work.
Read article
